ZIOP
Ziopharm Oncology, Inc.
Halal Rating :
Last Price
$1.71
Last updated:
Market Cap
-
7D Change
-1.72%
1 Year Change
1247.52%
Company Overview
Exchange
Next Earnings Date
Ziopharm Oncology, Inc. was a clinical-stage biopharmaceutical company that developed immuno-oncology therapies. The company merged with Alaunos Therapeutics in January 2022, and subsequently delisted from NASDAQ. The company no longer exists as a separate entity.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| June 30, 2024 | $4000.0 | $1.17m | - | - | 0.00% | 0.00% |
| March 31, 2024 | $1000.0 | $1.74m | - | - | 0.00% | 0.00% |
Company Impact
Help us evaluate Ziopharm Oncology, Inc.'s impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.